Trial · NCT03564938
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Adverse Events | From the start of regorafenib treatment up to 30 days after the last dose of regorafenib | |
| Primary | Changes in Eastern Cooperative Oncology Group Performance Status (ECOG PS) | From the start of regorafenib treatment up to 30 days after the last dose of regorafenib | |
| Primary | Percentage of participants with change in worst grades for hematological and biochemical toxicities according to CTCAE version 4.03, based on laboratory measurements | From the start of regorafenib treatment up to 30 days after the last dose of regorafenib | |
| Primary | Change in Body weight (kg) | From the start of regorafenib treatment up to 30 days after the last dose of regorafenib | |
| Primary | Change in Body height (cm) | From the start of regorafenib treatment up to 30 days after the last dose of regorafenib | |
| Primary | Change in Systolic / Diastolic BP (mmHg) | From the start of regorafenib treatment up to 30 days after the last dose of regorafenib | |
| Primary | Change in heart rate (beats/min) | From the start of regorafenib treatment up to 30 days after the last dose of regorafenib | |
| Secondary | Disease control rate (DCR) | In each participant, every 8 weeks from the start of regorafenib until radiological disease progression, lost to follow-up, consent withdrawn or end of study, whichever occurs first | Defined as proportion of patients achieving complete response (CR), partial response (PR), or SD (stable disease) per Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1 |
| Secondary | Overall response rate (ORR) | In each participant, every 8 weeks from the start of regorafenib until radiological disease progression, lost to follow-up, consent withdrawn or end of study, whichever occurs first | Defined as proportion of patients achieving CR, and PR per RECIST v.1.1 |
| Secondary | Progression free survival (PFS) | In each participant, every 8 weeks from the start of regorafenib until radiological disease progression, lost to follow-up, consent withdrawn or end of study, whichever occurs first | Progression free survival is defined as the time from study drug assignment to progressive disease (PD) or death from any cause or date of last tumor assessment if the patient did not progress or die. |
| Secondary | Overall survival (OS) | In each participant, every 8 weeks from the start of regorafenib until death, lost to follow-up, consent withdrawn or end of study, whichever occurs first | Overall survival is defined as the time from study drug assignment to death from any cause or last date when the patient was known to be alive. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03564938/registered